nderstanding the mechanism of cancer cell growth
Not Applicable
- Conditions
- Health Condition 1: N72- Inflammatory disease of cervix uteriHealth Condition 2: N61- Inflammatory disorders of breast
- Registration Number
- CTRI/2020/03/023745
- Lead Sponsor
- DrK Satyamoorthy
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Subjects diagnosed with breast cancer and undergoing surgery
Subjects diagnosed with cervical cancer and undergoing surgery
Exclusion Criteria
1. Patients having any kind of infection
2. Patients having an auto-immune disorder
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Our study can reveal the upstream mechanism(s) responsible for IL-6 secretion which in turn aid in developing targeted blockers to inhibit the secretion of IL-6 from cancer associated fibroblasts at the tumor microenvironment. Identifcation of novel genes regulated by epigenetic changes which can be further targeted for diagnostic/prognostic/therapeutic purposesTimepoint: 5 years
- Secondary Outcome Measures
Name Time Method The developed in-house <br/ ><br>IL-6R and gp130 antibodies alone or in combination with the inhibitors for secretory stimulants may have potential anti-cancerous effect by selectively targeting IL-6 signaling pathway. <br/ ><br>Timepoint: 5years